Trial Profile
An Observational Clinical Study on the Safety and Efficacy of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 11 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD22-CAR-NK-cell-therapy-Allife-Medical-Science-and-Technology (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- Sponsors Allife Medical Science and Technology
- 29 Jan 2019 Planned initiation date changed from 1 Nov 2018 to 1 Mar 2019.
- 10 Oct 2018 New trial record